[A case of HER2 overexpressing recurrent breast cancer treated clinically showing a complete response to trastuzumab/paclitaxel combination therapy].
A 57-year-old female was diagnosed as local, lung, and multiple liver metastases in the 2 years and 6 months after surgery. As expression of HER2 showed 3+, we performed trastuzumab/paclitaxel combination therapy. After 3 cycles, a rapid complete response was seen clinically. It is suggested that trastuzumab/paclitaxel combination therapy might be a first-line treatment for HER2 overexpressing recurrent breast cancer which had not been treated previously with anthracycline drugs.